Previous 10 | Next 10 |
Codex DNA, Inc. (DNAY) Q2 2021 Earnings Conference Call August 10, 2021 05:00 PM ET Company Participants Jennifer McNealey - Chief Financial Officer Todd Nelson - Chief Executive Officer Dan Gibson - Chief Technology Officer Conference Call Participants Paul Knight - KeyBanc Brandon Couillard...
SAN DIEGO, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq: DNAY), a pioneer in automated benchtop synthetic biology systems, today reported financial results for the second quarter ended June 30, 2021. “During the second quarter, Codex DNA took a big step forward in ...
SAN DIEGO, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (NASDAQ: DNAY), a pioneer in automated benchtop synthetic biology systems, today announced a collaboration with researchers from the U.S. Department of Agriculture’s (USDA) Agricultural Research Service (ARS), Cornell Unive...
SAN DIEGO, Aug. 03, 2021 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq: DNAY), the pioneer in automated benchtop synthetic biology systems, today announced that it will release its second quarter 2021 financial results on Tuesday, August 10, 2021. Company management will host a conference cal...
libre de droit/iStock via Getty Images Codex DNA ([[DNAY]] +7.4%) signed a licensing and supply agreement with Maravai LifeSciences' ([[MRVI]] +1.8%) TriLink Biotechnologies division for the latter's CleanCap technology. Codex DNA will integrate the mRNA capping technology into its suite...
SAN DIEGO, July 21, 2021 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (NASDAQ: DNAY), a pioneer in automated benchtop synthetic biology systems, today announced a licensing and supply agreement with TriLink Biotechnologies, part of Maravai LifeSciences (NASDAQ: MRVI), for its industry-leading CleanC...
Shares of Codex DNA Inc. (NASDAQ:DNAY) traded today at $14.61, breaking its 52-week low. So far today approximately 205,000 shares have been exchanged, as compared to an average 30-day volume of 227,000 shares. Codex DNA Inc is a synthetic biology company focused on enabling researchers ...
Shares of Codex DNA Inc. (NASDAQ:DNAY) traded at a new 52-week low today of $15.41. Approximately 205,000 shares have changed hands today, as compared to an average 30-day volume of 218,000 shares. Codex DNA Inc is a synthetic biology company focused on enabling researchers to rapidly, a...
adrian825/iStock via Getty Images Psychedelic drug developers started as buys Citi, Credit Suisse, Canaccord Genuity, and Cantor Fitzgerald have initiated Atai Life Sciences ([[ATAI]] +2.3%) with buy/overweight ratings. Credit Suisse has a $25 price target on shares (~35% upside) Credit...
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. Economic reports in the week ahead It's that time again, as second-quarter earnings season kicks off in earnest with the usual early reports from banks - J...
News, Short Squeeze, Breakout and More Instantly...
Codex DNA Inc. Company Name:
DNAY Stock Symbol:
NASDAQ Market:
-- Record revenue of $6.7M in 3QFY22; Increase of 140% over $2.8M 3QFY 2021 -- BioXp® Kit Revenue increased to $884k, or 69% in 3QFY22 over 3QFY2021 -- Increases revenue guidance to $23 million to $25 million for the full year fiscal 2022 SAN DIEGO, Nov. 08, 2022 (GLOBE N...
SAN DIEGO, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Telesis Bio (Nasdaq: DNAY), a leader in automated multi-omic and synthetic biology solutions, today announced that it will release its third quarter 2022 financial results on Tuesday, November 8, 2022, after the market closes. In conjunction ...
SAN DIEGO, Oct. 19, 2022 (GLOBE NEWSWIRE) -- Telesis Bio (Nasdaq: DNAY), a leader in automated multi-omic and synthetic biology solutions, and Cellibre, a leading manufacturing technology company, today announced initiation of work under a collaboration to optimize the development and valid...